Fetal neonatal hyperthyroidism: diagnostic and therapeutic approachment

Area of Science:

• Endocrinology
• Obstetrics
• Neonatology

Background:

• Fetal and neonatal hyperthyroidism can arise in infants of mothers with Graves' disease.
• Maternal TSH receptor stimulating antibodies cross the placenta, affecting fetal thyroid function.
• Fetal TSH receptors become responsive after 20 weeks gestation, increasing susceptibility.

Purpose of the Study:

• To review diagnostic criteria for fetal and neonatal hyperthyroidism.
• To outline therapeutic strategies for managing these conditions.
• To highlight challenges in diagnosis and treatment.

Main Methods:

• Review of existing literature on fetal and neonatal hyperthyroidism.
• Analysis of diagnostic indicators including fetal tachycardia, goiter, and bone age.
• Examination of maternal treatment protocols and their impact on neonates.

Main Results:

• Diagnosis confirmed by fetal tachycardia, goiter, and bone age advancement.
• Neonatal hyperthyroidism risk is elevated with maternal antithyroid drug requirement and high antibody levels.
• Delayed clinical manifestation in neonates due to maternal antithyroid medication.

Conclusions:

• Fetal and neonatal hyperthyroidism require careful diagnosis and management.
• Symptoms can mimic sepsis or congenital viral infections, necessitating differential diagnosis.
• Understanding antibody transfer and fetal receptor responsiveness is key.